Now I have a thorough understanding of the paper and the calibration landscape. Let me compose the final review.

## Summary

ComputAgeBench proposes the first systematic, open-access benchmark for evaluating blood-based epigenetic aging clocks. It defines three principled criteria for selecting aging-accelerating conditions (AACs), collects and harmonizes 66 public DNA methylation datasets covering 19 conditions across ~10,400 samples, and evaluates 13 published clock models across four tasks: relative aging acceleration (AA2), absolute aging acceleration (AA1), chronological age prediction accuracy, and systematic prediction bias. A cumulative BenchScore aggregates the AA2 and bias-corrected AA1 scores into a single ranking.

## Strengths

- **Unprecedented scale of curated epigenetic aging data.** Harmonizing 66 public datasets covering 19 conditions across 50+ studies with unified metadata (10,410 samples; Section 3.3, Fig. 2E) is a substantial and reusable community resource. Prior comparative studies were small-scale, limited to chronological age prediction, or lacked standardized datasets (Section 2.2).

- **Principled, evidence-based AAC selection criteria.** The three criteria for AACs—decreased life expectancy even when treated, chronicity, and systemic manifestation (Section 3.1, Fig. 2B)—provide a reproducible framework that directly addresses the call from Moqri et al. (2024) for a priori biomarker formulations.

- **Four-task decomposition separates distinct clock quality dimensions.** AA2 (two-sample test with controls), AA1 (one-sample test without controls), accuracy, and bias probe different aspects of clock validity (Section 3.5). This enables nuanced interpretation—for example, HorvathV1/V2 excel at chronological age prediction (Med(|Δ|)=5.4 and 4.1 years) but achieve low AA2 scores (3 and 5), concretely illustrating the biomarkers paradox.

- **Biomarkers paradox articulation directly motivates the evaluation framework.** The discussion in Section 2.1 clearly connects the theoretical insight (minimizing chronological age prediction error drives Δ→0) to why accuracy alone is insufficient for evaluating biological age estimators—a point that justifies the entire benchmark's design.

- **Key empirical finding: all clocks fail on CVD and metabolic diseases.** Every model scores 0/3 on CVD and 0/4 on MBD in the AA2 task (Fig. 3E). This is an important negative result that generalizes smaller-scale observations and highlights a concrete limitation of current blood-based clocks for clinically important condition classes.

- **Blood-based clocks are implicitly attuned to immune conditions.** The AA2 results show ISD (predominantly HIV) is the only class where most clocks succeed (Section 5), with a biologically motivated explanation: blood DNAm reflects immune cell composition directly affected by HIV.

## Weaknesses

### Fatal
None.

### Major

- **BenchScore effectively nullifies AA1 for positively-biased clocks, undermining the "unifying score" claim.** The penalty coefficient in Eq. (2), (1 − max(0, Med(Δ))/Med(|Δ|)), approaches 0 as bias approaches the absolute error. For GrimAgeV2 (AA1=20, Med(Δ)=9.3, Med(|Δ|)=9.8), the coefficient is ≈0.05, reducing its AA1 contribution from 20 to ~1.0. For Zhang19_EN (AA1=19, Med(Δ)=9.6, Med(|Δ|)=10.5), the AA1 contribution drops from 19 to ~1.6. The BenchScore thus reduces to approximately the AA2 score for all positively-biased clocks, making AA1 nearly irrelevant in the aggregate. While the paper acknowledges "there could be a more optimal solution" (Section 3.6), no sensitivity analysis demonstrates the ranking is stable under alternative formulations, nor is the asymmetric treatment of positive vs. negative bias theoretically justified. This matters because the BenchScore is the paper's central aggregation mechanism and is used to declare PhenoAgeV2 the "most robust" clock—yet the ranking is essentially just the AA2 ranking for most clocks.

- **The benchmark cannot distinguish clock failure from absence of epigenetic signal in certain conditions, yet scores clocks as failing in both cases.** When all 13 clocks score 0 on CVD (0/3) and MBD (0/4) in the AA2 task, the paper acknowledges three possible explanations (covariate shift, conditions may not accelerate blood epigenetic aging, multidimensionality of aging; Section 5), but the scoring mechanism treats all zeros identically as clock failures. This is an inherent limitation of any benchmark that uses condition-level pass/fail scoring without ground truth about which conditions should produce blood-detectable epigenetic acceleration. The paper should more prominently caveat the interpretation of AA2 scores for condition classes where all clocks score 0, and ideally provide auxiliary analyses (e.g., negative controls with healthy subsamples) to distinguish low power from genuine absence of signal.

### Minor

- **No procedure described for verifying non-overlap between benchmark data and clock training data.** The paper states "we also ensured that no data in the benchmark was used to train any of the selected clocks" (Section 3.4), but both benchmark data and clock training data come from public GEO datasets, making accidental overlap plausible. Without describing the verification method (e.g., matching GEO accession numbers, sample IDs), this critical claim cannot be independently assessed.

- **Small minimum sample sizes for parametric tests without normality verification.** The threshold of 5 AAC samples per dataset (Section 3.2) is insufficient for reliably verifying the normality assumption underlying the Welch's t-test and one-sample t-test. The paper justifies parametric tests by appealing to properties of linear regression models used in clock construction (Section 3.5), but the normality of training residuals does not guarantee normality of Δ distributions in small external samples. No effect sizes, power analyses, or normality checks are reported.

- **ISD class dominated by HIV, limiting generalizability of immune-related conclusions.** The finding that "blood-based clocks are implicitly attuned to immune system conditions" (Section 5) rests heavily on HIV data, which directly affects the immune cells from which blood DNAm is derived. Whether this extends to other immune conditions remains unknown.

- **The abstract's claim of "comprehensive benchmarking" overstates the scope.** The paper only evaluates properties 1 and 2 of 4 (explicitly stated in the introduction), covers only blood tissue (65/66 datasets), includes no aging-decelerating conditions, and is restricted to Illumina microarray platforms. The scope is meaningful but the adjective is overclaimed.

### Trivial
None.

## Nice-to-Haves

- Reporting effect sizes (e.g., Cohen's d for AA2, mean Δ for AA1) alongside p-values would help distinguish "tiny but significant" from "large and significant" effects, especially given varying sample sizes across datasets.
- A sensitivity analysis of BenchScore to alternative formulations (e.g., symmetric treatment of bias, different penalty functions) would strengthen the claim that the ranking is robust.
- A negative control analysis (testing whether clocks detect spurious acceleration in age-matched healthy subsamples) would help distinguish clock failure from condition-level absence of signal for CVD/MBD.
- Releasing the benchmark as a versioned software package with documented API would facilitate community adoption beyond the provided Colab notebook.

## Removed Points

These points are flagged to be removed, treat them with caution:

- **Harsh Critic's claim that "the benchmark's scoring is invalid for any condition where the ground truth of blood epigenetic acceleration is unknown."** The word "invalid" overstates the issue. The AA2 task with healthy controls provides a relative measure that is interpretable even without absolute ground truth. The concern is about interpretation, not validity. Downgraded to Major (uncertainty in interpretation) rather than Fatal.

- **Harsh Critic's claim of "asymmetric penalty—negatively-biased clocks are doubly penalized."** A negatively-biased clock naturally has a harder time passing the one-sample t-test (Δ_AAC > 0), which reduces its AA1 score. The BenchScore gives it no additional penalty (coefficient = 1). This is not "double penalizing" — it's that the AA1 test itself is harder to pass for negatively-biased clocks. The BenchScore is designed to correct for inflation from positive bias, not to compensate for deflation from negative bias. The critic's characterization is misleading.

- **Harsh Critic's claim that "the paper does not clearly justify why it only benchmarks properties 1 and 2 beyond data availability."** The paper explicitly states in the introduction that properties 3 and 4 require mortality/morbidity data that is "highly sensitive and are generally not publicly available" and discusses this further in Appendix A.7. The justification is clear.

- **Harsh Critic's concern about "no correction applied across clocks" for multiple comparisons.** The paper's purpose is to evaluate each clock independently against the same panel, not to make simultaneous statistical inferences across clocks. No correction is needed.

- **Harsh Critic's demand for "effect size analysis alongside p-values" and "power analysis."** These are good suggestions (included in Nice-to-Haves) but not required for a benchmark paper; the pass/fail scoring with FDR correction is a standard approach.

- **Harsh Critic's demand for non-overlap verification as a "significant reproducibility gap."** This is a valid concern (included in Minor) but "significant reproducibility gap" overstates it—the claim can be verified by checking the cited training datasets against the benchmark's GEO accession numbers.

- **Harsh Critic's request to "release the benchmark as a proper software package."** The paper already provides a runnable Colab notebook for full reproducibility. A software package would be nice but is not a core flaw.

- **Strength Finder's claim that "BenchScore correctly identifies PhenoAgeV2 as the top model by penalizing GrimAgeV2's inflated AA1 performance—demonstrating that the benchmark can distinguish genuine biological-age sensitivity from systematic artifact."** This claim overstates what the BenchScore does. As analyzed above, the formula essentially eliminates AA1 for all positively-biased clocks, so it doesn't "distinguish" sensitivity from artifact so much as it discards one component entirely for a large class of clocks.

- **Strength Finder's claim that "ensures no data leakage between clock training and benchmark evaluation" as a strength.** While the paper claims this, no verification procedure is described, so this cannot be confirmed as a demonstrated strength.

## Novel Insights

The key insight emerging from the review synthesis is that ComputAgeBench's most valuable contribution is not its aggregate score but its decomposition of clock quality into distinct dimensions. The tension between AA2 and chronological age prediction accuracy—where the best age predictors (HorvathV1/V2) are among the worst at detecting accelerated aging, and vice versa—is the most compelling empirical finding, directly embodying the biomarkers paradox the paper articulates theoretically. The BenchScore's attempt to unify these dimensions, while well-motivated, actually obscures this tension by collapsing it into a single number. A benchmark that leaned into the multi-dimensional nature of clock quality—providing radar charts or Pareto frontiers rather than a single aggregate—might better serve the community's need to understand which clocks are best for which purposes.

## Suggestions

- Replace or supplement BenchScore with a multi-dimensional visualization (e.g., radar plots or Pareto analysis across AA2, AA1, accuracy, and bias) that preserves the informative tension between tasks rather than collapsing it.
- Add a "negative control" analysis: for condition classes where all clocks score 0, test whether any clock detects spurious acceleration in healthy subsamples matched to the AAC age distribution. This would help distinguish "clocks can't detect it" from "there's nothing to detect in blood."
- Report effect sizes alongside p-values in supplementary materials to enable readers to assess practical significance independently of sample-size-driven statistical significance.
- Provide a brief description of the data non-overlap verification procedure (even a sentence describing the method, e.g., matching GEO accessions) to substantiate this important claim.

## Evaluation

**Originality:** The benchmark fills a genuine gap—no systematic, open-access benchmark for epigenetic aging clocks existed previously. The AAC selection criteria and four-task decomposition are novel. The BenchScore aggregation is original but has the structural issues noted above.

**Importance of research question:** High. The field of epigenetic aging clocks is growing rapidly with no standardized evaluation, and clinical trials of longevity drugs need validated biomarkers. A reliable benchmark would have significant impact.

**Claims support:** The data collection and individual task results are well-supported. The BenchScore's claim to provide a reliable "unifying" score is weakened by the structural flaw that nullifies AA1 for positively-biased clocks. The paper's most important findings (second-generation clocks outperform, all clocks fail on CVD/MBD, blood clocks attuned to immune conditions) are supported by the individual task data regardless of the BenchScore.

**Soundness of experiments:** Reasonable for a benchmark paper. The parametric testing framework with FDR correction is standard, though the small sample sizes and unverified normality assumption are limitations. The 66-dataset panel with 13 clocks is substantial.

**Clarity:** Well-organized with clear methodology overview (Fig. 2) and structured task definitions (Fig. 3). The biomarkers paradox discussion is clearly articulated.

**Value to community:** High for the data collection and task decomposition; moderate for the BenchScore, which needs refinement.

## Score and Decision

**Calibration anchors:**
- **High-scoring benchmarks (7–9):** BigCodeBench (9.0, Oral) — principled test-case design, validated metrics, 1,140 tasks; PLENCH (7.5, Spotlight) — comprehensive benchmarking with model selection criteria; MMIE (8.0, Oral) — automated scoring validated against human annotations. ComputAgeBench has comparable data curation effort but weaker metric validation than these.
- **Medium-scoring benchmarks (4–6):** DGEB (5.5, Reject) — similar profile of genomic embedding benchmark with limited task coverage and insufficient baseline comparisons; GNN benchmark paper (6.0, Reject) — proposes new evaluation metric revealing interesting findings but with metric design concerns. ComputAgeBench is comparable: strong data curation but metric design issues.
- **Low-scoring papers (<3):** Project MPG (1.5, Reject) — ad hoc aggregation metric with arbitrary scoring hierarchy and no validation. ComputAgeBench is clearly above this tier; its metric, while imperfect, is motivated by a real problem (positive bias inflation) and produces interpretable results.

ComputAgeBench sits in the medium tier alongside DGEB and the GNN benchmark paper. Its data collection is a genuine contribution, and the individual task results are valuable, but the BenchScore's structural flaw and the inability to distinguish clock failure from absence of signal in certain conditions limit the reliability of the "unifying score" claim. The paper would be stronger if it presented the multi-dimensional results as the primary contribution and treated BenchScore as a preliminary aggregation requiring community refinement—as the authors themselves acknowledge. This is a solid and needed first step, but not yet the definitive evaluation framework the field needs.

MY FINAL SCORE: <pineapple>5.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>